3.8 Review

Symptomatic Uncomplicated Diverticular Disease (SUDD): Practical Guidance and Challenges for Clinical Management

Journal

CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY
Volume 16, Issue -, Pages 29-43

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/CEG.S340929

Keywords

colonic diverticulosis; diverticulitis; irritable bowel syndrome; microbiota; treatment; probiotic

Ask authors/readers for more resources

Symptomatic Uncomplicated Diverticular Disease (SUDD) is a chronic condition characterized by local abdominal pain and bowel movement changes. It impairs quality of life and is associated with low-grade inflammation. Risk factors include age, genetic predisposition, obesity, physical inactivity, low-fiber diet, and smoking. The pathogenesis of SUDD involves fecal microbiota alterations, neuro-immune enteric interactions, and muscular system dysfunction. Treatment aims to improve symptoms and quality of life through a healthy lifestyle, probiotics, and medications like Rifaximin and Mesalazine. Surgery may be considered for patients with treatment failure and impaired quality of life. However, further studies are needed to evaluate the efficacy and safety of these interventions.
Symptomatic Uncomplicated Diverticular Disease (SUDD) is a syndrome within the diverticular disease spectrum, characterized by local abdominal pain with bowel movement changes but without systemic inflammation. This narrative review reports current knowledge, delivers practical guidance, and reveals challenges for the clinical management of SUDD. A broad and common consensus on the definition of SUDD is still needed. However, it is mainly considered a chronic condition that impairs quality of life (QoL) and is characterized by persistent left lower quadrant abdominal pain with bowel movement changes (eg, diarrhea) and low-grade inflammation (eg, elevated calprotectin) but without systemic inflammation. Age, genetic predisposition, obesity, physical inactivity, low-fiber diet, and smoking are considered risk factors. The pathogenesis of SUDD is not entirely clarified. It seems to result from an interaction between fecal microbiota alterations, neuro-immune enteric interactions, and muscular system dysfunction associated with a low-grade and local inflammatory state. At diagnosis, it is essential to assess baseline clinical and Quality of Life (QoL) scores to evaluate treatment efficacy and, ideally, to enroll patients in cohort studies, clinical trials, or registries. SUDD treatments aim to improve symptoms and QoL, prevent recurrence, and avoid disease progression and complications. An overall healthy lifestyle - physical activity and a high-fiber diet, with a focus on whole grains, fruits, and vegetables - is encouraged. Probiotics could effectively reduce symptoms in patients with SUDD, but their utility is missing adequate evidence. Using Rifaximin plus fiber and Mesalazine offers potential in controlling symptoms in patients with SUDD and might prevent acute diverticulitis. Surgery could be considered in patients with medical treatment failure and persistently impaired QoL. Still, studies with well-defined diagnostic criteria for SUDD that evaluate the safety, QoL, effectiveness, and cost-effectiveness of these interventions using standard scores and comparable outcomes are needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available